The last time I wrote about Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), it was in a Seeking Alpha article entitled “Recursion: Path Forward For REC-994 Remains Despite Mixed Response.” ...

See the 10 stocks » Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI stocks. As artificial intelligence continues to reshape industries ...

In this article, we are going to take a look at where Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stands against other stocks highlighted in Jim Cramer's latest calls. Jim Cramer in a recent ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

After hours: 7:59:47 p.m. EST ...

Latest on RXRX: Exclusive BAC Article: Recursion Pharmaceuticals; REC-2282 NF2 Treatment Data Q4 Of 2024, REC-4881 FAP Results 1st Half Of 2025 And Catalysts ...